Healthcare That Never Settles

Prescription Refills IconRefills Prescription Refills IconPatient Portal
MENU

Medical Weight Loss Programs with
Emerging Treatment Options

Telemedicine Consultations, Treatment Education, and Provider-Guided Care for Eligible Patients

Inside the Research: Retatrutide and the Future of Metabolic Science

California Trim Clinic provides this page strictly for educational and informational purposes. It is not medical advice and does not reflect a treatment offered by our practice. Retatrutide is an investigational compound not approved by the FDA for any use, and we do not prescribe, dispense, or study it.

WHAT RETATRUTIDE MEANS FOR PATIENTS RIGHT NOW

1
Retatrutide is an investigational triple hormone receptor agonist being studied in clinical trials.
2
Clinical trial results may not predict individual outcomes outside a controlled research setting.
3
Research studies use specific patient criteria, dosing protocols, monitoring, and safety oversight.
4
Retatrutide is not FDA-approved and should not be represented as an available treatment option.
5
A licensed provider can help patients understand currently available medical weight loss options.
LET’S TALK ABOUT YOUR optIONs

How Triple-Receptor Research Is Being Studied

Retatrutide is being studied for its activity on GLP-1, GIP, and glucagon receptors. This research is still investigational and should not be interpreted as a guarantee of safety, effectiveness, or availability.

GLP-1

GLP-1 pathways are involved in appetite, digestion, and blood sugar regulation. A licensed provider can explain how approved GLP-1 medications work and whether they may be appropriate for a patient.

GIP

GIP pathways are being studied for their role in insulin response and metabolic regulation. Clinical relevance depends on the specific medication, patient profile, and treatment setting.

GLUCAGON RECEPTOR


Glucagon receptor activity is being studied for its role in energy balance and metabolism. Claims about targeted fat loss or midsection fat loss should not be made.

Together, these pathways are part of ongoing clinical research. Individual treatment decisions should be based on medical history, current evidence, medication availability, and provider judgment.

California Trim Clinic offers Licensed-Provider Consultations for Medical Weight Loss.
If Medication-Based Care is Appropriate, your Provider can Discuss Available Treatment Options, Potential Benefits, Risks, and Limitations. Compounded Medications, when Legally Available and Prescribed for a Patient-Specific Need, are not FDA-Approved.

Understanding Different Medical Weight Loss Pathways

Feature Retatrutide Semaglutide Tirzepatide
Current Status Investigational; not FDA-approved FDA-approved options exist for certain patients FDA-approved options exist for certain patients
Pathway Focus GLP-1, GIP, and glucagon activity under study GLP-1 receptor pathway GLP-1 and GIP receptor pathways
Patient Conversation Education only; not an approved treatment option May be reviewed by a licensed provider when appropriate May be reviewed by a licensed provider when appropriate
Best Next Step Start with questions and care team guidance Review benefits, risks, and eligibility Review benefits, risks, and eligibility

Provider-Guided. Transparent. Telemedicine-Based.

Your care begins with a licensed-provider review. When medication is prescribed, fulfillment depends on clinical eligibility, legal availability, and pharmacy requirements. Patients should never purchase injectable medications from research supply websites or unverified online sellers.

Every care plan should be based on your health history, provider review, realistic expectations, and clear follow-up guidance.

Start With a Licensed Medical Weight Loss Consultation

Prescription treatment is available only when a licensed medical provider determines it is medically appropriate. Some medications discussed by providers may be compounded pursuant to a patient-specific prescription when legally available. Compounded Medications are not FDA-Approved, and FDA does not Evaluate Compounded Medications for Safety or Effectiveness.

Important Disclaimer on Retatrutide Information

Retatrutide is investigational and is not FDA-approved. Information about Retatrutide is provided for educational purposes only and should not be interpreted as a claim that Retatrutide is safe, effective, or appropriate for any person. Any medication should be used only under the guidance of a licensed medical provider and only when permitted under applicable law.
OK